U.S. Markets closed

Dynavax Technologies Corporation (DVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.18-0.11 (-1.18%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.29
Open9.32
Bid9.17 x 2200
Ask9.21 x 4000
Day's Range8.90 - 9.33
52 Week Range3.58 - 12.44
Volume1,295,501
Avg. Volume2,745,600
Market Cap1.052B
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-0.78
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.67
  • Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
    PR Newswire

    Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

    Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m. E.T.

  • Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial
    Benzinga

    Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial

    Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, combined with two adjuvants, alum and Dynavax Technologies Corporation’s (NASDAQ: DVAX) CpG 1018. Over 4,000 volunteers in the U.K. have been randomized in the Phase 3 trial “Cov-Compare,” which compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001,

  • Why Dynavax Stock Is Rising Today
    Motley Fool

    Why Dynavax Stock Is Rising Today

    What happened Shares of Dynavax Technologies (NASDAQ: DVAX) were up by 3.6% as of 11:38 a.m. EDT on Thursday after having gained as much as 6.9% earlier in the session. The stock's rise came following the company's announcement that it has signed a deal with Bavarian Nordic to market and distribute its hepatitis B vaccine Heplisav B in Germany.